<DOC>
	<DOCNO>NCT01814748</DOCNO>
	<brief_summary>This study examine safety efficacy once-weekly omarigliptin participant 18 &lt; 45 year age Type 2 diabetes mellitus inadequate glycemic control . The study hypothesis treatment omarigliptin compare placebo provide great reduction hemoglobin A1c ( A1C ) participants 24 week .</brief_summary>
	<brief_title>A Study Safety Efficacy Omarigliptin ( MK-3102 ) ≥18 &lt; 45 Year-Old Participants With Type 2 Diabetes Mellitus Inadequate Glycemic Control ( MK-3102-028 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Has type 2 diabetes mellitus Currently antihyperglycemic agent ( AHA ) least past 12 week treat omarigliptin time prior study participation Participant one following : 1 . Male 2 . Female reproductive potential 3 . Female reproductive potential agrees remain abstinent heterosexual activity use ( partner use ) 2 acceptable method contraception prevent pregnancy study 21 day last dose study drug History type 1 diabetes mellitus history ketoacidosis History hypersensitivity dipeptidylpeptidase4 ( DPP4 ) inhibitor Currently participate participate clinical trial past 12 week Is weight loss program maintenance phase ; weight loss medication past 6 month ; undergone bariatric surgery within 12 month prior study participation Has undergone surgical procedure within 4 week study participation plan major surgery study Is likely require treatment ≥14 consecutive day repeat course pharmacologic dos corticosteroid Is currently treat hyperthyroidism thyroid replacement therapy stable dose least 6 week Is expect undergo hormonal therapy preparation donate egg study , include 21 day follow last dose study drug History active liver disease ( nonalcoholic hepatic steatosis ) include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease Has human immunodeficiency virus ( HIV ) Has new worsen coronary heart disease congestive heart failure within past 3 month , follow disorder within past 3 month : 1 . Acute coronary syndrome 2 . Coronary artery intervention 3 . Stroke transient ischemic neurological disorder Has poorly control hypertension History malignancy ≤5 year prior study participation , except basal cell squamous cell skin cancer situ cervical cancer Has hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) Has positive urine pregnancy test Pregnant breastfeeding , expect conceive study , include 21 day follow last dose study drug User recreational illicit drug recent history drug abuse . Routinely consume &gt; 2 alcoholic drink per day &gt; 14 alcoholic drink per week , engage binge drinking . Has donate blood product phlebotomy ( &gt; 300 mL ) within 8 week study participation , intend donate blood product study receive , anticipated receive , blood product within 12 week study participation study Has clinically significant electrocardiogram abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Metformin</keyword>
	<keyword>Hypoglycemic Agents</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Therapeutic Uses</keyword>
</DOC>